97 related articles for article (PubMed ID: 28660502)
1. Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs.
Xu S; Zhao C; Jia Z; Wang X; Han Y; Yang Z
Arch Gynecol Obstet; 2017 Sep; 296(3):543-549. PubMed ID: 28660502
[TBL] [Abstract][Full Text] [Related]
2. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
Que KT; Zhou Y; You Y; Zhang Z; Zhao XP; Gong JP; Liu ZJ
J Exp Clin Cancer Res; 2018 Nov; 37(1):268. PubMed ID: 30400960
[TBL] [Abstract][Full Text] [Related]
4. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
5. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
6. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).
Hu H; Li S; Cui X; Lv X; Jiao Y; Yu F; Yao H; Song E; Chen Y; Wang M; Lin L
J Biol Chem; 2013 Apr; 288(16):10973-85. PubMed ID: 23436656
[TBL] [Abstract][Full Text] [Related]
7. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
8. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
9. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes.
Yang F; Guo L; Cao Y; Li S; Li J; Liu M
Med Sci Monit; 2018 Sep; 24():6506-6516. PubMed ID: 30219819
[TBL] [Abstract][Full Text] [Related]
11. The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.
Chen SM; Chou WC; Hu LY; Hsiung CN; Chu HW; Huang YL; Hsu HM; Yu JC; Shen CY
PLoS One; 2015; 10(6):e0128472. PubMed ID: 26115122
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.
Wei C; Luo Q; Sun X; Li D; Song H; Li X; Song J; Hua K; Fang L
Int J Clin Exp Pathol; 2015; 8(7):7729-39. PubMed ID: 26339338
[TBL] [Abstract][Full Text] [Related]
13. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
Tommasi S; Pinto R; Danza K; Pilato B; Palumbo O; Micale L; De Summa S
Oncotarget; 2016 Dec; 7(49):80363-80372. PubMed ID: 27385001
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells.
Dong Q; Li C; Che X; Qu J; Fan Y; Li X; Li Y; Wang Q; Liu Y; Yang X; Qu X
Oncotarget; 2016 Dec; 7(50):82338-82353. PubMed ID: 27494897
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells.
Hu Q; Gong JP; Li J; Zhong SL; Chen WX; Zhang JY; Ma TF; Ji H; Lv MM; Zhao JH; Tang JH
Asian Pac J Cancer Prev; 2014; 15(13):5137-42. PubMed ID: 25040964
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.
Wang Y; Zhou P; Li P; Yang F; Gao XQ
Bioengineered; 2020 Dec; 11(1):536-546. PubMed ID: 32345117
[TBL] [Abstract][Full Text] [Related]
17. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Wang J; Sai K; Chen FR; Chen ZP
Cancer Chemother Pharmacol; 2013 Jul; 72(1):147-58. PubMed ID: 23645289
[TBL] [Abstract][Full Text] [Related]
18. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
19. Host relieves lnc-IRAK3-3-sequestered miR-891b to attenuate apoptosis in Enterovirus 71 infection.
Liao YW; Ho BC; Chen MH; Yu SL
Cell Microbiol; 2019 Sep; 21(9):e13043. PubMed ID: 31099182
[TBL] [Abstract][Full Text] [Related]
20. miR-21 regulates N-methyl-N-nitro-N'-nitrosoguanidine-induced gastric tumorigenesis by targeting FASLG and BTG2.
Yang Q; Xu E; Dai J; Wu J; Zhang S; Peng B; Jiang Y
Toxicol Lett; 2014 Aug; 228(3):147-56. PubMed ID: 24821435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
